Victor Perlroth, M.D., serves as the Chief Executive Officer and Chairman of the Board at KODIAK SCIENCES INC., a biopharmaceutical company focused on developing novel therapeutics for retinal diseases. Dr. Perlroth has been instrumental in steering the company towards its mission of addressing unmet medical needs in ophthalmology. With a robust background in medicine and business, he has played a pivotal role in advancing KODIAK's research and development initiatives, particularly in the realm of innovative drug delivery systems. Prior to joining KODIAK SCIENCES INC., Dr. Perlroth held various leadership positions in the biopharmaceutical industry. He has a distinguished career that spans over two decades, during which he has contributed significantly to the development and commercialization of several groundbreaking therapies. His expertise in clinical development and strategic planning has been crucial in navigating the complex landscape of drug development. Dr. Perlroth's commitment to improving patient outcomes is evident in his dedication to fostering a culture of innovation and excellence at KODIAK. As the CEO and Chairman of the Board, Dr. Perlroth oversees the overall strategic direction of KODIAK SCIENCES INC., ensuring that the company remains at the forefront of retinal disease research. His leadership has been vital in securing key partnerships and investments that have propelled the company's growth. Under his guidance, KODIAK has made significant strides in advancing its pipeline of potential treatments, bringing hope to patients suffering from debilitating eye conditions. Dr. Perlroth's vision for the company is to continue pushing the boundaries of science to deliver transformative therapies that can make a meaningful difference in people's lives.